In another AML study, leukemic stem cells, defined as CD34+CD38−, were shown to have heightened autophagy and increased chemoresistance upon treatment with JQ1, an epigenetic agent proposed to treat AML [16]. The gene discussed is CD34; the disease is acute myeloid leukemia.